市場調査レポート

ファーマコビジランス市場分析:治験段階別 (前臨床研究、第1相、第2相、第3相、第4相)、サービスプロバイダー別 (インハウス、委託アウトソーシング)、および2020年までのセグメント予測

Pharmacovigilance Market Analysis By Clinical Trial Phases (Preclinical Studies, Phase I/1, Phase II/2, Phase III/3, Phase IV/4 Trial), By Type Of Service Providers (In House, Contract Outsourcing) And Segment Forecasts To 2020

発行 Grand View Research, Inc. 商品コード 342335
出版日 ページ情報 英文 102 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
ファーマコビジランス市場分析:治験段階別 (前臨床研究、第1相、第2相、第3相、第4相)、サービスプロバイダー別 (インハウス、委託アウトソーシング)、および2020年までのセグメント予測 Pharmacovigilance Market Analysis By Clinical Trial Phases (Preclinical Studies, Phase I/1, Phase II/2, Phase III/3, Phase IV/4 Trial), By Type Of Service Providers (In House, Contract Outsourcing) And Segment Forecasts To 2020
出版日: 2015年02月15日 ページ情報: 英文 102 Pages
概要

世界のファーマコビジランス市場は2020年までに55億1,000万米ドルに達すると予測されています。薬物への有害反応の発生率上昇や厳しい薬剤安全性規定の導入などが市場の拡大を牽引しています。委託アウトソーシング分野は2020年まで13.1%の成長率で拡大すると見込まれています。

当レポートでは、世界のファーマコビジランス市場について分析し、治験段階別、サービスプロバイダー別見通し、および地域別動向などをまとめています。

第1章 エグゼクティブサマリー

第2章 ファーマコビジランス業界見通し

  • 市場セグメンテーション
  • 市場規模と成長見通し
  • 市場動向
    • 促進因子
    • 阻害因子
  • 優先される機会
  • PESTEL分析
  • 市場シェア分析:2013年

第3章 治験段階別見通し

  • 治験段階別市場シェア
  • 前臨床
  • 第0層
  • 第1相
  • 第2相
  • 第3相
  • 第4相

第4章 サービスプロバイダー別見通し

  • サービスプロバイダー別市場シェア
  • インハウス
  • 委託アウトソーシング

第5章 地域別見通し

  • 地域別市場シェア:2013年、2020年
  • 北米
  • 欧州
  • アジア太平洋地域
  • その他の諸国

第5章 競合環境

  • Accenture Plc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb
  • Clinquest Group B.V.
  • Cognizant Technology Solutions Corporation
  • Covance, Inc.
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline (GSK)
  • IBM Corporation
  • ICON, Plc
  • iGATE Corporation
  • iMEDGlobal Corporation
  • Infosys
  • Ipca Laboratories Ltd
  • Janssen Research & Development, LLC
  • Novartis International AG
  • PAREXEL International Corporation
  • Pfizer, Inc.
  • Pharmaceutical Product Development, Inc. (PPD, Inc.)
  • Sanofi Aventis
  • Synowlwedge LLC
  • Wipro Ltd.
  • PRA Health Sciences Inc
  • Quantum Solutions India
  • Quintiles Transnational Corporation
  • inVentiv Health Inc.
  • OptumInsight, Inc.
  • United BioSource Corporation
  • Ecron Acunova
  • Fortitude Clinical
  • ITClinical

第7章 調査方法と調査範囲

図表

目次

Global pharmacovigilance market is expected to reach USD 5.51 billion by 2020. Increasing incidence rates of adverse drug reaction and the introduction of stringent drug safety regulations are some key drivers of this market. ADR is responsible for approximately 5% of the hospitalization in developed countries annually, and this is expected to boost usage rates over the next six years. Pharmacovigilance has witnessed a significant rise in usage rates in the recent times owing to growing global geriatric population triggering a growth in demand for new drug development. Additionally, health regulatory authorities such as the U.S. FDA and EMEA (European Medicines Agency) are now emphasizing on electronic submission of data which is also expected to drive the pharmacovigilance market.

Contract outsourcing pharmacovigilance market is expected to grow at a lucrative rate of over 13.1% during the forecast period. Service flexibility and cost effectiveness associated with outsourcing are some key factors accounting for the segment's lucrative growth.

Further key findings from the study suggest:

Pharmacovigilance services found the largest application in phase 4/IV clinical trial studies in 2013. Greater applicability and relevance are some factors accounting for the segment's market position.

Contract outsourcing was the most revenue generating service provider segment in 2013. Minimization of upfront investments and reduction in fixed overhead costs are some factors expected to drive segment growth.

North America was the largest regional market, accounting for over 40.0% of the revenue in 2013. Presence of stringent healthcare regulations implemented by the U.S. FDA and high market penetration rates of electronic medical records are some factors responsible for its large share.

Asia Pacific is identified as the most lucrative market. Presence of a large pool of skilled labor and favorable business environments are some factors expected to drive regional market growth. Rapidly improving healthcare infrastructure in the emerging economies of India and China is also expected to provide new growth opportunities to the market participants.

Key players of this market include Quintiles Transnational Corporation, PAREXEL International, Clinquest Group BV, Pharmaceutical Product Development, Accenture Plc., Boehringer Ingelheim GmbH and Cognizant Technology Solutions

Providing customized end to end PV solutions & services and entering into strategic agreements are some key strategies adopted by these market players.

For the purpose of this study, Grand View Research has segmented the pharmacovigilance market on the basis of clinical trial phase, type of service provider and region:

Global Pharmacovigilance Clinical Trial Phase Outlook (Revenue, USD Million, 2012 - 2020)

  • Pre Clinical
  • Phase 0
  • Phase 1/I
  • Phase 2/II
  • Phase 3/III
  • Phase 4/IV

Global Pharmacovigilance Service Provider Outlook (Revenue, USD Million, 2012 - 2020)

  • In- House
  • Contract Outsourcing

Pharmacovigilance Regional Outlook (Revenue, USD Million, 2012 - 2020)

  • North America
  • Europe
  • Asia Pacific
  • RoW

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Pharmacovigilance- Industry Summary and Critical Success Factors (CSFs)

Chapter 2. Pharmacovigilance Industry Outlook

  • 2.1. Market Segmentation
  • 2.2. Market Size and Growth Prospects
  • 2.3. Pharmacovigilance - Market dynamics
    • 2.3.1. Market Driver Analysis
    • 2.3.2. Market Restraint Analysis
  • 2.4. Key Opportunities Prioritized
  • 2.5. Pharmacovigilance - PESTEL Analysis
  • 2.6. Pharmacovigilance Company Market Share Analysis, 2013

Chapter 3. Pharmacovigilance Clinical Trial Phase Outlook

  • 3.1. Pharmacovigilance market share, by clinical trial phase, 2013 & 2020
  • 3.2. Preclinical
    • 3.2.1. Preclinical Market Estimates and Forecasts, 2012 - 2020 (USD Million)
  • 3.3. Phase 0
    • 3.3.1. Phase 0 Market Estimates and Forecasts, 2012 - 2020 (USD Million)
  • 3.4. Phase I
    • 3.4.1. Phase I Market Estimates and Forecasts, 2012 - 2020 (USD Million)
  • 3.5. Phase II
    • 3.5.1. Phase II Market Estimates and Forecasts, 2012 - 2020 (USD Million)
  • 3.6. Phase III
    • 3.6.1. Phase III Market Estimates and Forecasts, 2012 - 2020 (USD Million)
  • 3.7. Phase IV
    • 3.7.1. Phase IV Market Estimates and Forecasts, 2012 - 2020 (USD Million)

Chapter 4. Pharmacovigilance Type of Service Provider Outlook

  • 4.1. Pharmacovigilance market share, by type of service provider, 2013 & 2020
  • 4.2. In- House
    • 4.2.1. In-House Market Estimates and Forecasts, 2012 - 2020 (USD Million)
  • 4.3. Contract Outsourcing
    • 4.3.1. Contract Outsourcing Market Estimates and Forecasts, 2012 - 2020 (USD Million)

Chapter 5. Pharmacovigilance Regional Outlook

  • 5.1. Pharmacovigilance market share by region, 2012 & 2020
  • 5.2. North America
    • 5.2.1. Market Estimates and Forecasts, by Clinical Trial Phase
    • 5.2.2. Market Estimates and Forecasts, by Type of Service Provider
  • 5.3. Europe
    • 5.3.1. Market Estimates and Forecasts, by Clinical Trial Phase
    • 5.3.2. Market Estimates and Forecasts, by Type of Service Provider
  • 5.4. Asia Pacific
    • 5.4.1. Market Estimates and Forecasts, by Clinical Trial Phase
    • 5.4.2. Market Estimates and Forecasts, by Type of Service Provider
  • 5.5. RoW
    • 5.5.1. Market Estimates and Forecasts, by Clinical Trial Phase
    • 5.5.2. Market Estimates and Forecasts, by Type of Service Provider

Chapter 6. Competitive Landscape

  • 6.1 Accenture Plc.
    • 6.1.1. Company Overview
    • 6.1.2. Financial Performance
    • 6.1.3. Product Benchmarking
    • 6.1.4. Strategic Initiatives
  • 6.2. Boehringer Ingelheim GmbH
    • 6.2.1. Company Overview
    • 6.2.2. Financial Performance
    • 6.2.3. Product Benchmarking
    • 6.2.4. Strategic Initiatives
  • 6.3. Bristol-Myers Squibb
    • 6.3.1. Company Overview
    • 6.3.2. Financial Performance
    • 6.3.3. Product Benchmarking
    • 6.3.4. Strategic Initiatives
  • 6.4. Clinquest Group B.V.
    • 6.4.1. Company Overview
    • 6.4.2. Financial Performance
    • 6.4.3. Product Benchmarking
    • 6.4.4. Strategic Initiatives
  • 6.5. Cognizant Technology Solutions Corporation
    • 6.5.1. Company Overview
    • 6.5.2. Financial Performance
    • 6.5.3. Product Benchmarking
    • 6.5.4. Strategic Initiatives
  • 6.6. Covance, Inc.
    • 6.6.1. Company Overview
    • 6.6.2. Financial Performance
    • 6.6.3. Product Benchmarking
    • 6.6.4. Strategic Initiatives
  • 6.7. F. Hoffmann-La Roche Ltd
    • 6.7.1. Company Overview
    • 6.7.2. Financial Performance
    • 6.7.3. Product Benchmarking
    • 6.7.4. Strategic Initiatives
  • 6.8. GlaxoSmithKline (GSK)
    • 6.8.1. Company Overview
    • 6.8.2. Financial Performance
    • 6.8.3. Product Benchmarking
    • 6.8.4. Strategic Initiatives
  • 6.9. IBM Corporation
    • 6.9.1. Company Overview
    • 6.9.2. Financial Performance
    • 6.9.3. Product Benchmarking
    • 6.9.4. Strategic Initiatives
  • 6.10. ICON, Plc
    • 6.10.1. Company Overview
    • 6.10.2. Financial Performance
    • 6.10.3. Product Benchmarking
    • 6.10.4. Strategic Initiatives
  • 6.11. iGATE Corporation
    • 6.11.1. Company Overview
    • 6.11.2. Financial Performance
    • 6.11.3. Product Benchmarking
    • 6.11.4. Strategic Initiatives
  • 6.12. iMEDGlobal Corporation
    • 6.12.1. Company Overview
    • 6.12.2. Financial Performance
    • 6.12.3. Product Benchmarking
    • 6.12.4. Strategic Initiatives
  • 6.13. Infosys
    • 6.13.1. Company Overview
    • 6.13.2. Financial Performance
    • 6.13.3. Product Benchmarking
    • 6.13.4. Strategic Initiatives
  • 6.14. Ipca Laboratories Ltd
    • 6.14.1. Company Overview
    • 6.14.2. Financial Performance
    • 6.14.3. Product Benchmarking
    • 6.14.4. Strategic Initiatives
  • 6.15. Janssen Research & Development, LLC
    • 6.15.1. Company Overview
    • 6.15.2. Financial Performance
    • 6.15.3. Product Benchmarking
    • 6.15.4. Strategic Initiatives
  • 6.16. Novartis International AG
    • 6.16.1. Company Overview
    • 6.16.2. Financial Performance
    • 6.16.3. Product Benchmarking
    • 6.16.4. Strategic Initiatives
  • 6.17. PAREXEL International Corporation
    • 6.17.1. Company Overview
    • 6.17.2. Financial Performance
    • 6.17.3. Product Benchmarking
    • 6.17.4. Strategic Initiatives
  • 6.18. Pfizer, Inc.
    • 6.18.1. Company Overview
    • 6.18.2. Financial Performance
    • 6.18.3. Product Benchmarking
    • 6.18.4. Strategic Initiatives
  • 6.19. Pharmaceutical Product Development, Inc. (PPD, Inc.)
    • 6.19.1. Company Overview
    • 6.19.2. Financial Performance
    • 6.19.3. Product Benchmarking
    • 6.19.4. Strategic Initiatives
  • 6.20. Sanofi Aventis
    • 6.20.1. Company Overview
    • 6.20.2. Financial Performance
    • 6.20.3. Product Benchmarking
    • 6.20.4. Strategic Initiatives
  • 6.21. Synowlwedge LLC
    • 6.21.1. Company Overview
    • 6.21.2. Financial Performance
    • 6.21.3. Product Benchmarking
    • 6.21.4. Strategic Initiatives
  • 6.22. Wipro Ltd.
    • 6.22.1. Company Overview
    • 6.22.2. Financial Performance
    • 6.22.3. Product Benchmarking
    • 6.22.4. Strategic Initiatives
  • 6.23. PRA Health Sciences Inc.
    • 6.23.1. Company Overview
    • 6.23.2. Financial Performance
    • 6.23.3. Product Benchmarking
    • 6.23.4. Strategic Initiatives
  • 6.24. Quantum Solutions India
    • 6.24.1. Company Overview
    • 6.24.2. Financial Performance
    • 6.24.3. Product Benchmarking
    • 6.24.4. Strategic Initiatives
  • 6.25. Quintiles Transnational Corporation
    • 6.25.1. Company Overview
    • 6.25.2. Financial Performance
    • 6.25.3. Product Benchmarking
    • 6.25.4. Strategic Initiatives
  • 6.26. inVentiv Health Inc.
    • 6.26.1. Company Overview
    • 6.26.2. Financial Performance
    • 6.26.3. Product Benchmarking
    • 6.26.4. Strategic Initiatives
  • 6.27. OptumInsight, Inc.
    • 6.27.1. Company Overview
    • 6.27.2. Financial Performance
    • 6.27.3. Product Benchmarking
    • 6.27.4. Strategic Initiatives
  • 6.28. United BioSource Corporation
    • 6.28.1. Company Overview
    • 6.28.2. Financial Performance
    • 6.28.3. Product Benchmarking
    • 6.28.4. Strategic Initiatives
  • 6.29. Ecron Acunova
    • 6.29.1. Company Overview
    • 6.29.2. Financial Performance
    • 6.29.3. Product Benchmarking
    • 6.29.4. Strategic Initiatives
  • 6.30. Fortitude Clinical
    • 6.30.1. Company Overview
    • 6.30.2. Financial Performance
    • 6.30.3. Product Benchmarking
    • 6.30.4. Strategic Initiatives
  • 6.31. ITClinical
    • 6.31.1. Company Overview
    • 6.31.2. Financial Performance
    • 6.31.3. Product Benchmarking
    • 6.31.4. Strategic Initiatives

Chapter 7. Methodology and Scope

  • 7.1. Research Methodology
  • 7.2. Research Scope & Assumption
  • 7.3. List of Data Sources

List of Tables

  • 1. Pharmacovigilance Market - Industry Summary & Critical Success Factors (CSFs)
  • 2. Global Pharmacovigilance Market Revenue, By Clinical Trial Phase, 2012 - 2020, Revenue (USD Million)
  • 3. Global Pharmacovigilance Market Revenue, By Type of Service Provider , 2012 - 2020, Revenue (USD Million)
  • 4. Global Pharmacovigilance Market Revenue, By Region, 2012 - 2020, Revenue (USD Million)
  • 5. Pharmacovigilance Market - Key market driver analysis
  • 6. Pharmacovigilance - Key market restraint analysis
  • 7. North America Pharmacovigilance Market Size And Trends, 2012 - 2020, Revenue (USD Million)
  • 8. North America Pharmacovigilance Market Revenue, By Clinical Trial Phase, 2012 - 2020 (USD Million)
  • 9. North America Pharmacovigilance Market Revenue, By Type of Service provider, 2012 - 2020 (USD Million)
  • 10. Europe Pharmacovigilance Market Size And Trends, 2012 - 2020, Revenue (USD Million)
  • 11. Europe Pharmacovigilance Market Revenue, By Clinical Trial Phase, 2012 - 2020 (USD Million)
  • 12. Europe Pharmacovigilance Market Revenue, By Type of service Provider, 2012 - 2020 (USD Million)
  • 13. Asia Pacific Pharmacovigilance Market Size And Trends, 2012 - 2020, Revenue (USD Million)
  • 14. Asia Pacific Pharmacovigilance Market Revenue, By Clinical Trial Phase, 2012 - 2020 (USD Million)
  • 15. Asia Pacific Pharmacovigilance Market Revenue, By Type of service Provider, 2012 - 2020 (USD Million)
  • 16. RoW Pharmacovigilance Market Size And Trends, 2012 - 2020, Revenue (USD Million)
  • 17. RoW Pharmacovigilance Market Revenue, By Clinical Trial Phase, 2012 - 2020 (USD Million)
  • 18. RoW Pharmacovigilance Market Revenue, By Type of Service Provider, 2012 - 2020 (USD Million)

List of Figures

  • 1. Pharmacovigilance: Market Segmentation
  • 2. Global Pharmacovigilance Market, 2012 - 2020, Revenue (USD Million)
  • 3. Pharmacovigilance Market Dynamics
  • 4. Key Opportunities Prioritized
  • 5. Pharmacovigilance Market - Porter's Analysis
  • 6. Pharmacovigilance Market - PESTEL Analysis
  • 7. Pharmacovigilance Company Market Share Analysis, 2013
  • 8. Pharmacovigilance Market Share, By Clinical Trial Phase, 2013 & 2020
  • 9. Pharmacovigilance Market Share, By Type of Service Provider, 2013 & 2020
  • 10. Pharmacovigilance Market Share, By Region, 2013 & 2020
Back to Top